Overview

Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study aims to look at how BAY 2402234 responds in body in patients with recurrent glioma.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborator:
Bayer